Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Protocadherin 7 and Castration Resistant Prostate Cancer

Key clinical point: The first time protocadherin 7 (PCDH7) is overexpressed in a large number of patients with castrate resistant prostate cancer (CRPC), suggests that PCDH7 may be an attractive target in subsets of patients with CRPC.

Major finding: PCDH7 amplification/mRNA upregulation was shown in 41% of patients in CRPC/ neuroendocrine prostate cancer (NEPC) dataset, as well as was overexpressed in CRPC cells.

Study details: PCDH7 expression was analyzed in CRPC/ NEPC dataset, and colony formation, cell migration, and invasion studies were performed.

Citation:

Shishodia G, et al. Prostate. 2019 Aug 26. doi: 10.1002/pros.23898.